Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma
Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma
Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy
ESMO 2024: Latest in bladder cancer - expert review
No OS improvement over chemo from capivasertib plus paclitaxel in advanced TNBC
Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours
ESMO 2024: Latest in EGFR mutated NSCLC
Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous cell carcinoma of the anal canal
Understanding the use of PARPi combinations to treat patients with mCRPC
TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer